112 filings
ARS
2023 FY
TCRX
Tscan Therapeutics Inc
30 Apr 24
Annual report to shareholders
4:14pm
DEFA14A
TCRX
Tscan Therapeutics Inc
30 Apr 24
Additional proxy soliciting materials
4:10pm
DEF 14A
TCRX
Tscan Therapeutics Inc
Definitive proxy
30 Apr 24
4:07pm
424B5
TCRX
Tscan Therapeutics Inc
17 Apr 24
Prospectus supplement for primary offering
9:58pm
8-K
TCRX
Tscan Therapeutics Inc
17 Apr 24
TScan Therapeutics Announces Launch of $125 million Proposed
6:25am
FWP
vg5iob3 fv03w
17 Apr 24
Free writing prospectus
6:20am
424B5
2c6t7
16 Apr 24
Prospectus supplement for primary offering
5:21pm
8-K
9qds r5yhryp56yb
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
EFFECT
2uu4yrzkmi
15 Apr 24
Notice of effectiveness
12:15am
8-K
kfys5wlgx8qgw
8 Apr 24
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert
8:17am
S-8
4g2sl41 yjhvt27
6 Mar 24
Registration of securities for employees
4:05pm
8-K
8gywx
6 Mar 24
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
uz9rut 2r1r73
29 Jan 24
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
7:15am
8-K
7z4z4sceegsfut 0r8
11 Dec 23
Regulation FD Disclosure
8:00am
8-K
7315xc01rftlh7h
7 Dec 23
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
7:15am
8-K
fcv4vz26ns8 r9ckomq
9 Nov 23
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am